enrollment at all U.S. and international sites. The trial remains on track for an expected data readout in 2026. Exhibit 99.1 Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress REDWOOD CITY, Calif., Nov 5, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS- addicted cancers, today announced its financial results for the quarter ended September 30, 2025, ...